Intensidad y duración de la respuesta inmune humoral a la vacuna para COVID 19 en trabajadores de la salud, utilizando una prueba de anticuerpos IgG cuantitativos
Barra lateral del artículo
Contenido principal del artículo
Resumen
Introduccion: La pandemia de COVID 19 ha afectado severamente a la humanidad, causando una alta morbilidad y mortalidad en todos los paises del mundo. El objetivo de este estudio fue determinar la intensidad y duración de la respuesta de anticuerpos IgG frente a la vacuna para COVID 19 en trabajadores de la salud. Materiales y métodos: Estudio descriptivo prospectivo longitudinal de evaluación de la respuesta inmune a la vacuna para COVID 19, con cuantificación de anticuerpos IgG para SARS CoV 2. Se realizaron mediciones a los 4, 8, y 12 meses post vacuna. Resultados: Primera medición (306 trabajadores): mediana de anticuerpos de 770.5 BAU/ml (RIQ: 338.7-2314.2); segunda medición (169 trabajadores): mediana de 185.7 BAU/ml (RIQ: 85.4-418.1); tercera medición (88 trabajadores): mediana de 3270 BAU/ml (RIQ:2480-3270). Mayor respuesta de anticuerpos en los trabajadores con antecedente de COVID 19. Discusión: La vacuna para COVID 19 genera una buena respuesta de anticuerpos, los cuales disminuyen en el tiempo y se recuperan con una dosis de refuerzo. La prueba de anticuerpos IgG cuantitativa contra RBD puede ser un buen correlato de protección.
Detalles del artículo
Citas
Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections the state of the art. Emerg Microbes Infect. 2020 Dec;9(1):747-756. PMID: 32196430; PMCID: PMC7172701. https://doi.org/10.1080/22221751.2020.1745095
Zhangkai J. Cheng, Jing Shan. 2019 Novel coronavirus: where we are and what we know. Infection (2020) 48:155-163. https://doi.org/10.1007/s15010-020-01401-y
Dreser A. Retos y avances en la vacunacion contra COVID-19 en Latinoamerica y el Caribe. Salud UIS. 2021; 53: e21002. https://doi.org/10.18273/saluduis.53.e:21002
Okba NMA, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Et al. Severe acute respiratory syndrome coronavirus 2 specific antibody responses in coronavirus disease 2019 patients. Emerg Infect Dis. 2020 Jul [Cited: 11/04/2020]. https://doi.org/10.3201/eid2607.200841
Ministerio de Salud y Protección Social de Colombia. Efectividad de las vacunas contra el COVID 19 en Colombia. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/MET/estudio efectividad-vacunas-colombia-msps.pdf. Fecha de consulta: 31/05/2022
Bal A, Pozzetto B, Trabaud MA, Escuret V, Rabilloud M, Langlois-Jacques C, Et al. Evaluation of high-throughput SARS CoV 2 serological assays in a longitudinal cohort of patients with mild COVID 19: clinical sensitivity, specificity and association with virus neutralization test. Clinical chemistry, hvaa336. Advance online publication. https://doi.org/10.1093/clinchem/hvaa336
Resman Rus K, Korva M, Knap N, Avsic Zupanc T, Poljak M. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS CoV 2 spike protein receptor binding domain in comparison to the neutralization assay. J Clin Virol. 2021 Jun;139:104820. Epub 2021 Apr 10. PMID: 33865031; PMCID: PMC8035809. https://doi.org/10.1016/j.jcv.2021.104820
Irsara C, Egger AE, Prokop W, Nairz M, Loacker L, Sahanic S, Pizzini A, Sonnweber T, Holzer B, Mayer W, Schennach H, Loeffler-Ragg J, Bellmann-Weiler R, Hartmann B, Tancevski I, Weiss G, Binder CJ, Anliker M, Griesmacher A, Hoermann G. Clinical validation of the Siemens quantitative SARS CoV 2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Clin Chem Lab Med. 2021 Apr 9;59(8):1453-1462. https://doi.org/10.1515/cclm-2021-0214
Forni G, Mantovani A. COVID 19 vaccines: where we stand and challenges ahead. Cell Death & Differentiation (2021) 28:626-639 https://doi.org/10.1038/s41418-020-00720-9
NIBSC. WHO International Standard First WHO International Standard for anti-SARS CoV 2 immunoglobulin (human) NIBSC code: 20/136 Instructions for use (Version 2.0, Dated17/12/2020). Disponible en: https://www.nibsc.org/documents/ifu/20-136.pdf. Fecha de consulta: 25/04/2021
Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Et al. WHO International Standard for anti SARS CoV 2 immunoglobulin. www.thelancet.com Vol 397 April 10, 2021 (Letter). https://doi.org/10.1016/S0140-6736(21)00527-4
Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, Bell JI, Newton JN, Farrar J, Diamond I, Rourke E, Howarth A, Marsden BD, Hoosdally S, Jones EY, Stuart DI, Crook DW, Peto TEA, Pouwels KB, Eyre DW, Walker AS; COVID 19 Infection Survey team. Antibody responses to SARS CoV 2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021 Sep;6(9):1140-1149. Epub 2021 Jul 21. PMID: 34290390; PMCID: PMC8294260. https://doi.org/10.1038/s41564-021-00947-3
Ebinger, J.E., Fert-Bober, J., Printsev, I. et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS CoV 2. Nat Med 27, 981-984 (2021). https://doi.org/10.1038/s41591-021-01325-6
Ciccone EJ, Zhu DR, Ajeen R, Lodge EK, Shook-Sa BE, Boyce RM, Aiello AE. SARS CoV 2 seropositivity after infection and antibody response to mRNA-based vaccination. medRxiv [Preprint]. 2021 Feb 22:2021.02.09.21251319. PMID: 33619498; PMCID: PMC7899463. https://doi.org/10.1101/2021.02.09.21251319
Gobbi F, Buonfrate D, Moro L, Rodari P, Piubelli C, Caldrer S, Et al. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS CoV 2 Infection. Viruses. 2021 Mar 5;13(3):422. PMID: 33807957; PMCID: PMC8001674. https://doi.org/10.3390/v13030422
Perkmann T, Mucher P, Perkmann-Nagele N , Radakovics A, Repl M, Koller T, Et al. The comparability of Anti-Spike SARS CoV 2 antibody tests is time-dependent: a prospective observational study. medRxiv https://doi.org/10.1101/2021.08.26.21262426
Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, Humphries HE, Jepson B, Kelly EJ, Plested E, Shoemaker K, Thomas KM, Vekemans J, Villafana TL, Lambe T, Pollard AJ, Voysey M; Oxford COVID Vaccine Trial Group. Correlates of protection against symptomatic and asymptomatic SARS CoV 2 infection. Nat Med. 2021 Nov;27(11):2032-2040. Epub 2021 Sep 29. PMID: 34588689; PMCID: PMC8604724. https://doi.org/10.1101/2021.06.21.21258528
Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS CoV 2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5. Erratum in: Lancet. 2021 Jul 17;398(10296):212. PMID: 33964222; PMCID: PMC8099315. https://doi.org/10.1016/S0140-6736(21)01555-5
Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, Kose S, Erdinc FS, Akalin EH, Tabak OF, Pullukcu H, Batum O, Simsek Yavuz S, Turhan O, Yildirmak MT, Koksal I, Tasova Y, Korten V, Yilmaz G, Celen MK, Altin S, Celik I, Bayindir Y, Karaoglan I, Yilmaz A, Ozkul A, Gur H, Unal S; CoronaVac Study Group. Efficacy and safety of an inactivated wholevirion SARS CoV 2 vaccine (CoronaVac): interim results of a double blind, randomised, placebo controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8. Erratum in: Lancet. 2022 Jan 29;399(10323):436. PMID: 34246358; PMCID: PMC8266301. https://doi.org/10.1016/S0140-6736(21)02787-2
Picazo JJ. Vacuna frente al COVID 19 [Vaccine against COVID 19]. Rev Esp Quimioter. 2021 Dec;34(6):559-598. Spanish. doi: 10.37201/req/085.2021. Epub 2021 Jun 28. PMID: 34180617; PMCID: PMC8638770.
Sanchez L, Oviedo S, Pifano M, Ojeda DS, Pascuale CA, Mazzitelli B, et al. Antibody durability at 1 year after Sputnik V vaccination. Lancet Infect Dis. 2022 May 22(5): 589-590. Published online 2022 Mar 16. https://doi.org/10.1016/S1473-3099(22)00176-122. Kichatova VS, Asadi FA, Potemkin IA, Zlobin SP, Perfilieva OM, Valuev Elliston VT, et al. Assessment of Diagnostic Specificity of Anti-SARS CoV 2 Antibody Tests and Their Application for Monitoring of Seroconversion and Stability of Antiviral Antibody Response in Healthcare Workers in Moscow. Microorganisms 2022, 10, 429. https://doi.org/10.3390/microorganisms10020429
Kozakai R, Hoshi K, Izumi Y, Takahashi S. Assessment of antibody titer after third doses of COVID 19 mRNA vaccination in healthy volunteers. J Lab Med 2022; 46(2): 151-153. https://doi.org/10.1515/labmed-2022-0008
Eyre DW, Lumley SF, Wei J, Cox S, James T, Justice A, Et al. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status. Clin. Microbiol. Infect. (2021). https://doi.org/10.1016/j.cmi.2021.05.041
Cordova E, Lespada MI, Cecchini D, Nieto N, Palonski S, Badran M, y col. Evaluacion de la respuesta de los anticuerpos IGG especificos contra SARS CoV 2 en el personal de salud con el esquema completo de la vacuna Sputnik V (Gam-COVID-Vac). Vacunas. 2022. https://doi.org/10.1016/j.vacun.2022.01.008
Bonelli M, Mrak D, Tobudic S, Sieghart D, Koblischke M, Mandl P, Et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS CoV 2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial. medRxiv 2021.09.05.21263125; https://doi.org/10.1101/2021.09.05.21263125
Chemaitelly H , AlMukdad S, Paravila J , Ayoub HH , Yassine HM, Benslimane FM. y col. SARS CoV 2 vaccine effectiveness in immunosuppressed kidney transplant recipients. medRxiv 2021.08.07.21261578; https://doi.org/10.1101/2021.08.07.21261578
Koup RA, Donis RO, Gilbert PB, Li AW, Shah NA, Houchens CR. A government-led effort to identify correlates of protection for COVID 19 vaccines. Nature Medicine. 2021; 27:1489-1496 https://doi.org/10.1038/s41591-021-01484-6